No other industry would tolerate avoidable annual losses of $637 billion, but that’s exactly what pharma is doing by not investing in adherence. Now is the time to start recovering that revenue ...

Inquiry Vol. 58, January-December 2021 Patients’ Adherence to Anti-diabetic Med... Introduction: A number of medications have been demonstrated to lower blood glucose. However, current-day management ...

Reports Q4 revenue $307M, consensus $300.01M. “We delivered solid financial results for Q4 2024, including returning to year-over-year revenue ...